CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Fulcrum Therapeutics, Inc. - FULC CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread 0.06
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Fulcrum Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 4.84
Open* 4.71
1-Year Change* -4.07%
Day's Range* 4.67 - 4.94
52 wk Range 2.25-15.00
Average Volume (10 days) 1.33M
Average Volume (3 months) 45.31M
Market Cap 343.12M
P/E Ratio -100.00K
Shares Outstanding 61.82M
Revenue 3.04M
EPS -1.81
Dividend (Yield %) N/A
Beta 2.05
Next Earnings Date Nov 6, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low
Jun 29, 2022 4.91 0.20 4.25% 4.71 4.97 4.65
Jun 28, 2022 4.84 -0.30 -5.84% 5.14 5.14 4.78
Jun 27, 2022 5.19 0.18 3.59% 5.01 5.25 4.86
Jun 24, 2022 5.12 0.14 2.81% 4.98 5.21 4.90
Jun 23, 2022 5.07 0.30 6.29% 4.77 5.11 4.77
Jun 22, 2022 4.88 0.50 11.42% 4.38 5.12 4.38
Jun 21, 2022 4.46 -0.15 -3.25% 4.61 4.90 4.46
Jun 17, 2022 4.55 0.20 4.60% 4.35 4.89 4.31
Jun 16, 2022 4.34 0.23 5.60% 4.11 4.41 4.05
Jun 15, 2022 4.39 0.32 7.86% 4.07 4.42 4.07
Jun 14, 2022 4.23 0.16 3.93% 4.07 4.40 3.97
Jun 13, 2022 4.15 -0.42 -9.19% 4.57 4.62 4.11
Jun 10, 2022 4.89 -0.12 -2.40% 5.01 5.18 3.19
Jun 9, 2022 8.07 0.09 1.13% 7.98 8.41 7.89
Jun 8, 2022 8.26 0.58 7.55% 7.68 8.59 7.68
Jun 7, 2022 8.04 0.68 9.24% 7.36 8.31 7.35
Jun 6, 2022 7.52 -0.59 -7.27% 8.11 8.46 7.48
Jun 3, 2022 7.93 0.65 8.93% 7.28 8.02 7.28
Jun 2, 2022 7.51 0.86 12.93% 6.65 7.93 6.65
Jun 1, 2022 6.87 -0.19 -2.69% 7.06 7.24 6.55

Fulcrum Therapeutics, Inc. Events

Time (UTC) Country Event
Monday, November 6, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 Fulcrum Therapeutics Inc Earnings Release
Q3 2023 Fulcrum Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Thursday, March 7, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Fulcrum Therapeutics Inc Earnings Release
Q4 2023 Fulcrum Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 6.342 19.163 8.823 0 0
Total Operating Expense 118.903 100.217 80.434 84.217 33.498
Selling/General/Admin. Expenses, Total 41.694 30.516 21.392 13.145 8.314
Research & Development 76.782 69.701 59.042 71.072 25.184
Operating Income -112.561 -81.054 -71.611 -84.217 -33.498
Interest Income (Expense), Net Non-Operating 1.511 0.518
Other, Net 2.69 0.207 0.792 0.029 0.392
Net Income Before Taxes -109.871 -80.847 -70.819 -82.677 -32.588
Net Income After Taxes -109.871 -80.847 -70.819 -82.677 -32.588
Net Income Before Extra. Items -109.871 -80.847 -70.819 -82.677 -32.588
Net Income -109.871 -80.847 -70.819 -82.677 -32.588
Total Adjustments to Net Income 0 -7.128 -6.559
Income Available to Common Excl. Extra. Items -109.871 -80.847 -70.819 -89.805 -39.147
Income Available to Common Incl. Extra. Items -109.871 -80.847 -70.819 -89.805 -39.147
Diluted Net Income -109.871 -80.847 -70.819 -89.805 -39.147
Diluted Weighted Average Shares 44.991 35.361 25.354 22.6544 22.2934
Diluted EPS Excluding Extraordinary Items -2.44207 -2.28633 -2.79321 -3.96412 -1.75599
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -2.43258 -2.28633 -2.79321 -3.96412 -1.75599
Revenue 6.342 19.163 8.823
Unusual Expense (Income) 0.427
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.88 0.295 0.685 1.183 1.882
Revenue 0.88 0.295 0.685 1.183 1.882
Total Operating Expense 28.172 28.235 28.658 25.538 36.117
Selling/General/Admin. Expenses, Total 10.323 11.52 10.13 9.707 11.098
Research & Development 17.849 16.715 18.566 15.366 25.019
Operating Income -27.292 -27.94 -27.973 -24.355 -34.235
Other, Net 3.509 3.161 1.838 0.617 0.165
Net Income Before Taxes -23.783 -24.779 -26.135 -23.738 -34.07
Net Income After Taxes -23.783 -24.779 -26.135 -23.738 -34.07
Net Income Before Extra. Items -23.783 -24.779 -26.135 -23.738 -34.07
Net Income -23.783 -24.779 -26.135 -23.738 -34.07
Income Available to Common Excl. Extra. Items -23.783 -24.779 -26.135 -23.738 -34.07
Income Available to Common Incl. Extra. Items -23.783 -24.779 -26.135 -23.738 -34.07
Diluted Net Income -23.783 -24.779 -26.135 -23.738 -34.07
Diluted Weighted Average Shares 61.794 59.722 52.155 46.213 40.89
Diluted EPS Excluding Extraordinary Items -0.38488 -0.41491 -0.5011 -0.51366 -0.83321
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.38488 -0.41491 -0.50183 -0.5036 -0.83321
Unusual Expense (Income) -0.038 0.465
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 207.519 225.998 119.51 100.083 74.095
Cash and Short Term Investments 202.921 218.162 112.914 96.713 72.797
Cash & Equivalents 35.098 35.412 57.052 96.713 72.797
Total Receivables, Net 1.081 4.11 2.707 0.111 0.501
Accounts Receivable - Trade, Net 1.081 4.11 2.707 0.111 0.135
Prepaid Expenses 3.517 3.726 3.815 2.975 0.559
Other Current Assets, Total 0 0.074 0.284 0.238
Total Assets 226.685 235 129.577 110.439 85.771
Property/Plant/Equipment, Total - Net 15.969 7.368 8.397 9.205 10.546
Property/Plant/Equipment, Total - Gross 26.631 15.637 14.515 13.152 12.504
Accumulated Depreciation, Total -10.662 -8.269 -6.118 -3.947 -1.958
Other Long Term Assets, Total 3.197 1.634 1.67 1.151 1.13
Total Current Liabilities 16.725 19.199 26.725 12.14 4.229
Accounts Payable 3.638 4.788 4.079 2.186 1.263
Accrued Expenses 12.048 9.157 7.212 5.397 2.157
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0.017 0.05 0.046
Other Current Liabilities, Total 1.039 5.254 15.417 4.507 0.763
Total Liabilities 27.743 23.461 34.396 23.286 9.771
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 11.018 4.262 7.671 11.146 5.542
Total Equity 198.942 211.539 95.181 87.153 76
Preferred Stock - Non Redeemable, Net 0 0 139.67
Common Stock 0.052 0.041 0.028 0.023 0.011
Additional Paid-In Capital 612.025 514.362 316.775 237.931 4.443
Retained Earnings (Accumulated Deficit) -412.338 -302.467 -221.62 -150.801 -68.124
Treasury Stock - Common 0 0 0 0 0
Total Liabilities & Shareholders’ Equity 226.685 235 129.577 110.439 85.771
Total Common Shares Outstanding 52.0992 40.6262 27.9416 22.6544 22.2934
Short Term Investments 167.823 182.75 55.862
Other Equity, Total -0.797 -0.397 -0.002
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 302.83 207.519 227.727 174.247 200.064
Cash and Short Term Investments 297.84 202.921 221.789 168.973 195.112
Cash & Equivalents 34.734 35.098 90.938 40.153 33.313
Short Term Investments 263.106 167.823 130.851 128.82 161.799
Total Receivables, Net 1.264 1.081 1.237 1.492 1.208
Accounts Receivable - Trade, Net 1.264 1.081 1.237 1.492 1.208
Prepaid Expenses 3.726 3.517 4.701 3.782 3.697
Other Current Assets, Total 0.047
Total Assets 321.12 226.685 247.805 195.233 220.248
Property/Plant/Equipment, Total - Net 15.167 15.969 16.888 17.788 18.276
Property/Plant/Equipment, Total - Gross 26.395 26.631 26.959 27.248 27.067
Accumulated Depreciation, Total -11.228 -10.662 -10.071 -9.46 -8.791
Other Long Term Assets, Total 3.123 3.197 3.19 3.198 1.908
Total Current Liabilities 14.407 16.725 14.699 22.121 18.288
Accounts Payable 3.778 3.638 2.728 5.385 6.003
Accrued Expenses 9.883 12.048 10.557 14.943 9.231
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 0.746 1.039 1.414 1.793 3.054
Total Liabilities 24.864 27.743 26.391 34.478 31.088
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 10.457 11.018 11.692 12.357 12.8
Total Equity 296.256 198.942 221.414 160.755 189.16
Common Stock 0.062 0.052 0.052 0.041 0.041
Additional Paid-In Capital 733.962 612.025 608.486 524.247 518.604
Retained Earnings (Accumulated Deficit) -437.117 -412.338 -386.203 -362.465 -328.395
Treasury Stock - Common 0 0 0 0
Other Equity, Total -0.651 -0.797 -0.921 -1.068 -1.09
Total Liabilities & Shareholders’ Equity 321.12 226.685 247.805 195.233 220.248
Total Common Shares Outstanding 61.759 52.0992 52.0499 41.0082 40.6836
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -109.872 -80.847 -70.819 -82.677 -32.588
Cash From Operating Activities -97.05 -78.478 -53.655 -39.483 -22.562
Cash From Operating Activities 2.414 2.515 2.379 2.053 1.345
Non-Cash Items 13.502 11.743 7.282 29.815 2.159
Cash Interest Paid 0 0 0.004 0.007 0.01
Changes in Working Capital -3.094 -11.889 7.503 11.326 6.522
Cash From Investing Activities 12.413 -129.669 -57.138 -0.944 -8.981
Capital Expenditures -1.963 -1.713 -1.342 -0.853 -8.981
Cash From Financing Activities 84.323 186.507 71.132 64.343 105.025
Issuance (Retirement) of Stock, Net 84.323 186.525 71.375 0.215 105.095
Issuance (Retirement) of Debt, Net 0 -0.018 -0.05 -0.045 -0.07
Net Change in Cash -0.314 -21.64 -39.661 23.916 73.482
Other Investing Cash Flow Items, Total 14.376 -127.956 -55.796 -0.091
Financing Cash Flow Items -0.193 64.173
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -24.779 -109.872 -83.736 -59.998 -25.928
Cash From Operating Activities -24.116 -97.05 -77.354 -49.472 -22.106
Cash From Operating Activities 0.566 2.414 1.823 1.212 0.536
Non-Cash Items 2.887 13.502 10.832 7.367 4.2
Cash Interest Paid 0
Changes in Working Capital -2.79 -3.094 -6.273 1.947 -0.914
Cash From Investing Activities -93.941 12.413 48.775 51.054 19.659
Capital Expenditures -0.171 -1.963 -1.847 -1.564 -0.246
Other Investing Cash Flow Items, Total -93.77 14.376 50.622 52.618 19.905
Cash From Financing Activities 117.693 84.323 84.105 3.159 0.348
Issuance (Retirement) of Stock, Net 117.693 84.323 84.105 3.159 0.348
Issuance (Retirement) of Debt, Net 0 0 0 0
Net Change in Cash -0.364 -0.314 55.526 4.741 -2.099
Financing Cash Flow Items

Fulcrum Therapeutics, Inc. Company profile

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc. clinical-stage biopharmaceutical company. The Company focuses on improving the lives of patients with genetically defined rare diseases. The Company have developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders. The Company is using Its proprietary product engine to identify and validate drug targets and develop product candidates to address diseases caused by the mis-expression of certain genes. Its product candidate includes losmapimod, is a small molecule that is developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, is a small molecule designed to bind embryonic ectoderm development (EED).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Fulcrum Therapeutics Inc revenues increased from $8.8M to $19.2M. Net loss increased 14% to $80.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 17% to $65.2M (expense), General and administrative increase of 37% to $23.9M (expense).

Industry: Biotechnology & Medical Research (NEC)

26 Landsdowne Street
CAMBRIDGE
MASSACHUSETTS 02139
US

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

BTC/USD

26,625.25 Price
-0.030% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Oil - Crude

90.14 Price
+0.770% 1D Chg, %
Long position overnight fee 0.0415%
Short position overnight fee -0.0634%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.52 Price
+0.700% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

ETH/USD

1,598.51 Price
+0.560% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading